{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:54:58Z","timestamp":1777452898034,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>No data are available on the clinical presentation and virological pattern in the case of failure of interferon (IFN)-free regimens in patients with genotype-3h. In this paper authors identified the virological and clinical characteristics of patients with genotype-3h treated with suboptimal or not indicated IFN-free regimens for the misclassification of HCV genotype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 87 consecutive patients with failure to an IFN-free regimen were re-tested for HCV genotype by HCV NS5B sequencing; the 26 patients identified as harbouring HCV-3 were enrolled.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 26 patients enrolled, 4 (15.4%) harboured sub-genotype-3h and 22 (84.6%) 3a. All patients were Italian. Patients with genotype-3a infection were younger (median age 56 years, range 47\u201378) compared to those with genotype-3h infection (median 74 years, range 65\u201379; P&lt;0.006). With regard to the failed direct-acting antiviral (DAA)-regimens, three of the four patients with genotype-3h (75%) had been treated with an ineffective DAA regimen (paritaprevir, ombitasvir, dasabuvir \u00b1 ribavirin for 3 months) more frequently than those with genotype-3a (13.6%; P=0.02), because of previous erroneous identification of HCV-1 genotype. NS5A resistance-associated substitutions (RASs) were observed in 10 (45.4%) genotype-3a-infected patients and in 2 (50%) with genotype-3h. NS5B RASs were observed in only two genotype-3a-infected patients and in none of the 3h-infected patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the first time genotype-3h has been identified in Italian patients failing an IFN-free regimen, in the majority of cases because of a misclassification of the HCV genotype.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp3228","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T05:48:56Z","timestamp":1520228936000},"page":"605-609","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["HCV Genotype-3h, a Difficult-to-Diagnose Sub-Genotype in the DAA Era"],"prefix":"10.1177","volume":"23","author":[{"given":"Carmine","family":"Minichini","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania L. Vanvitelli, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Starace","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania L. Vanvitelli, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"De Pascalis","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania L. Vanvitelli, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Macera","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania L. Vanvitelli, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Occhiello","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania L. Vanvitelli, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara","family":"Caroprese","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania L. Vanvitelli, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Vitrone","sequence":"additional","affiliation":[{"name":"Internal Medicine, University of Campania & AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Iovinella","sequence":"additional","affiliation":[{"name":"Infectious Diseases, ASL Napoli 1, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Guerrera","sequence":"additional","affiliation":[{"name":"Internal Medicine, University of Campania L. Vanvitelli, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Masarone","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, University of Salerno, Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Coppola","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania L. Vanvitelli, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,10,1]]},"reference":[{"key":"bibr1-IMP3228","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26141"},{"key":"bibr2-IMP3228","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.03.025"},{"key":"bibr3-IMP3228","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.05.008"},{"key":"bibr4-IMP3228","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26744"},{"key":"bibr5-IMP3228","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"key":"bibr6-IMP3228","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.027"},{"key":"bibr7-IMP3228","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.10.012"},{"key":"bibr8-IMP3228","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","volume":"66","author":"EASL Recommendations on Treatment of Hepatitis C.","year":"2017","journal-title":"J Hepatol"},{"key":"bibr9-IMP3228","unstructured":"American Association for the Study of Liver Disease and Infectious Diseases Society of America. Recommendations for Testing, Managing, and Treating Hepatitis C. 2016."},{"key":"bibr10-IMP3228","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13383"},{"key":"bibr11-IMP3228","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"bibr12-IMP3228","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.065128-0"},{"key":"bibr13-IMP3228","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10909"},{"key":"bibr14-IMP3228","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3134"},{"key":"bibr15-IMP3228","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.05.032"},{"key":"bibr16-IMP3228","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12781"},{"key":"bibr17-IMP3228","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv564"},{"key":"bibr18-IMP3228","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.049668-0"},{"key":"bibr19-IMP3228","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23787"},{"key":"bibr20-IMP3228","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17101679"},{"key":"bibr21-IMP3228","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24527"},{"key":"bibr22-IMP3228","unstructured":"American Association for the Study of Liver Disease and Infectious Diseases Society of America. Recommendations for Testing, Managing, and Treating Hepatitis C. 2017."},{"key":"bibr23-IMP3228","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27895"},{"key":"bibr24-IMP3228","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25022"},{"key":"bibr25-IMP3228","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.09.008"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3228","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:34Z","timestamp":1777380754000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP3228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,1]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.3851\/IMP3228"],"URL":"https:\/\/doi.org\/10.3851\/imp3228","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,1]]}}}